Catalog Home Page

Research directions in genetic predispositions to Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis

Manolio, T.A., Hutter, C.M., Avigan, M., Cibotti, R., Davis, R.L., Denny, J.C., Grenade, L.L., Wheatley, L.M., Carrington, M.N., Chantratita, W., Chung, W.H., Dalton, A.D., Hung, S.I., Lee, M.T.M., Leeder, J.S., Lertora, J.J.L., Mahasirimongkol, S., McLeod, H.L., Mockenhaupt, M., Pacanowski, Michael, Phillips, E.J., Pinheiro, S., Pirmohamed, M., Sung, C., Suwankesawong, W., Trepanier, L.A., Tumminia, S.J., Veenstra, D., Yuliwulandari, R. and Shear, N.H. (2017) Research directions in genetic predispositions to Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis. Clinical Pharmacology & Therapeutics, 103 (3). pp. 390-394.

Link to Published Version: https://doi.org/10.1002/cpt.890
*Subscription may be required

Abstract

Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is one of the most devastating of adverse drug reactions (ADRs) and was, until recently, essentially unpredictable. With the discovery of several risk alleles for drug-induced SJS/TEN and the demonstration of effectiveness of screening in reducing incidence, the stage is set for implementation of preventive strategies in populations at risk. Yet much remains to be learned about this potentially fatal complication of commonly used drugs.

Publication Type: Journal Article
Murdoch Affiliation: Institute for Immunology and Infectious Diseases
Publisher: Nature Publishing Group
Copyright: © 2017 American Society for Clinical Pharmacology and Therapeutics
URI: http://researchrepository.murdoch.edu.au/id/eprint/40298
Item Control Page Item Control Page